Antisense oligonucleotide intralesional therapy for human PC-3 prostate tumors carried in athymic nude mice

Journal of Surgical Oncology

Volumn 62, Issue 3, 1996, Pages 194-200

  Rubenstein, Marvin ^a   Mirochnik, Yelena ^a   Chou, Pauline ^a   Guinan, Patrick ^a  

^a Hektoen Institute for Medical Research   (United States)

Author keywords

antisense oligonucleotides; growth factor deprivation therapy; prostate cancer

Indexed keywords

COMPLEMENTARY RNA; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DOSE RESPONSE; GENE DOSAGE; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; RNA TRANSCRIPTION; TRANSCRIPTION REGULATION; TREATMENT OUTCOME; TUMOR REGRESSION;

ANIMALS; BASE SEQUENCE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INFUSION PUMPS, IMPLANTABLE; INJECTIONS, INTRALESIONAL; MALE; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDES, ANTISENSE; PROSTATIC NEOPLASMS; REMISSION INDUCTION; TUMOR CELLS, CULTURED;

EID: 0029951177     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199607)62:3<194::AID-JSO9>3.0.CO;2-2     Document Type: Article

References (16)

1. Ratajczak MZ, Hijiya N, Catani L, et al.: Acute- and chronicphase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligonucleotides. Blood 79:1956-1961, 1992.
2. Bayever E, Iversen PL, Bishop MR, et al.: Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial. Antisense Res Dev 3:383-390, 1993.
3. IBC Conference on Commercializing Oligonucleotide-Based Therapeutics; Clinical Trials and Applications (Coronado, CA; February 9-10, 1995); International Business Communications, 225 Turnpike Rd., Southborough, MA.
4. Rubenstein M, Muchnik S, Dunea G, Guinan P: Antisense treatment of prostate cancer. J Cell Biochem 17E(suppl):198a, 1993.
5. Rubenstein M, Muchnik S, Dunea G, et al.: Inoculation of prostatic tumors with antisense oligonucleotides against mRNA encoding growth factors and receptors. In Einhorn J, Nord CE, Norrby SR (eds): "Recent Advances in Chemotherapy." Washington, DC: American Society for Microbiology, 1994, p 898-899.
6. Rubenstein M, Muchnik S, Dunea G, Guinan P: Histologic evaluation of PC-3 tumors treated with antisense oligonucleotides. J Urol 149:175a, 1993.
7. Rubenstein M, Dunea G, Guinan P: Growth factor deprivation therapy utilizing antisense oligonucleotides. Drugs News Perspect 7:517-524, 1994.
8. Kaighn ME, Narayan S, Ohnuki Y, et al.: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17:16-23, 1979.
9. Hofer DR, Sherwood ER, Bromberg WD, et al.: Autonomous growth of androgen-independent human prostatic carcinoma cells: Role of transforming growth factor-alpha. Cancer Res 51:2780-2785, 1991.
10. Isaacs JT, Hukku B: Nonrandom involvement of chromosome 4 in the progression of rat prostatic cancer. Prostate 13:165-188, 1988.
11. Akhtar S, Kole R, Juliano RL: Stability of antisense DNA oligonucleotide analogs in cellular extracts and sera. Life Sci 49:1793-1801, 1991.
12. Thompson DM, Gill GN: The EGF receptor: Structure, regulation and potential role in malignancy. Cancer Surv 4:767-788, 1985.
13. Wilding GE, Valverius C, Knabbe C, Gelmann EP: Role of transforming growth factor-alpha in human prostate cancer cell growth. Prostate 15:1-12, 1989.
14. Morris GL, Dodd JG: Epidermal growth factor mRNA levels in human prostatic tumors and cell lines. J Urol 143:1272-1275, 1990.
15. Aaronson SA, Tronick SR: Constitutive activation of growth factor signaling pathways in cancer cells. In Broder S (ed): "Molecular Foundations of Oncology." Baltimore: Williams & Wilkins, 1991, p 41-53.
16. Rubenstein M, Mirochnik Y, McKiel CF, Guinan P: Antisense oligonucleotide induced growth factor deprivation therapy in PC-3 cells enhance bcl-2 expression. J Urol 153:270a, 1995.